Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
CAR NK Cells for B-Cell Cancers
Recruiting1 awardPhase 1
Cleveland, Ohio
This trial is testing a new therapy called NKX019 (allogeneic CAR NK cells targeting CD19) to see if it is safe and tolerable for patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service